Back to News
Market Impact: 0.42
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Source: seekingalpha.com
Healthcare & BiotechAnalyst InsightsCompany Fundamentals
Pharvaris maintained a Strong Buy rating after pivotal Phase 3 successes for both its on-demand and prophylactic hereditary angioedema (HAE) therapies. In the RAPIDe-3 trial, PHVS reported rapid symptom relief with a median time of 1.28 hours, supporting the clinical value proposition for its HAE pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
PHVS0.86
More News
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- AI Debt Binge Is Reordering Risk Hierarchy With Emerging Bonds
- Teradyne at Goldman Sachs Communacopia + Technology Conference: ai push widens
- Signet (SIG) Q2 2027 Earnings Call Transcript
- ‘My boss is the Chinese customer’: Walmart China CEO Christina Zhu on how the Fortune 500 company is thriving in a tough retail market
- Sunbelt Rentals (SUNB) Q1 2027 Earnings Call Transcript